Healthcare
Deal focus: C -Bridge brings more co-investment to Ascletis
C-Bridge Capital participates in a $100 million Series B round of funding for biotechnology Ascletis alongside existing backer Goldman Sachs and a number of its LPs
C-Bridge buys control of China’s Anrei Medical
Healthcare-focused PE firm C-Bridge Capital has acquired a controlling stake in Anrei Medical Device, a China-based invasive medical devices manufacturer, for $25 million.
China's Frontier Biotechnologies gets $43m round
Frontier Biotech, a China-based pharmaceutical company that works on HIV treatments, has received RMB300 million ($43 million) in Series C funding, led by Huaxin Century Investment Group.
PE-backed New Century Healthcare targets $129m HK IPO
New Century Healthcare, a Chinese pediatric hospital operator backed by CDH Investments and Boyu Capital, is planning to raise HK$1 billion ($129 million) via a Hong Kong IPO.
Israel's Yozma to invest $41m in Korean health tech start-ups
Israeli venture capital firm Yozma Group has agreed to invest KRW50 billion ($41.4 million) in Korean biotechnology and healthcare start-ups, starting in the first half of 2017.
C-Bridge leads $100m round for China's Ascletis
Healthcare-focused PE firm C-Bridge Capital has led a Series B round of funding worth $100 million for Ascletis, a Chinese biotechnology company that specializes in treatments for liver disease.
Everstone invests $35m in India's OmniActive Health
The Everstone Group has committed $35 million to Indian nutraceuticals ingredient supplier OmniActive Health Technologies. It is the firm’s third pharmaceuticals investment in less than a year.
TA backs India drug ingredients manufacturer
TA Associates has invested INR1.72 billion ($25.5 million) in listed Indian drug ingredients manufacturer Shilpa Medicare.
MSPEA commits $25m to India's ZCL Chemicals
Morgan Stanley Private Equity Asia (MSPEA) has invested INR1.7 billion ($25 million) in ZCL Chemicals, an India-based pharmaceuticals company that focuses on niche therapeutic areas such as the central nervous system, antiretroviral treatments and controlled...
Japan's AGC Asahi Glass buys PE-owned CMC Biologics
Japanese glass, ceramic and chemicals maker AGC Asahi Glass has paid JPY60 billion ($510 million) for CMC Biologics, a Denmark-based biopharmaceutical manufacturer backed by several private equity firms.
AVCJ Awards 2016: Deal of the Year - Early Stage Tech: Zai Lab
Zai Lab has carved a niche licensing pre-clinical findings from the West for development into drugs in China, but its ambitions are global. Several VCs have faith in the project
India's VC-backed Practo acquires US analytics start-up
Indian clinic management software developer and doctor search portal Practo, which is supported by several VC investors, has acquired US-based analytics firm Enlightiks.
PE-backed Claris exits division to US strategic
Claris Lifesciences, an Indian drug maker with several PE backers, has agreed to exit its injectables division to US-based generic pharmaceutical developer Baxter International.
Three GPs chosen to manage Australia biomedical fund
OneVentures, Brandon Capital and BioScience Managers have been selected to manage the Australian government’s A$500 million ($375 million) Biomedical Translation Fund (BTF).
Samara to invest $25m in India's SMT
Samara Capital has agreed to invest up to $25 million for a significant stake in Indian medical device manufacturer Sahajanand Medical Technologies (SMT).
IVFA makes partial exit from India's Syngene
India Value Fund Advisors (IVFA) has made a partial exit from India-listed pharmaceuticals company Syngene International, selling an approximately 1.6% holding for INR1.9 billion ($27.7 million).
Mandarin acquires Italian pharmaceuticals maker
Europe-Asia cross-border focused PE firm Mandarin Capital Partners has committed EUR16.4 million ($17.7 million) for a majority stake in Italian pharmaceutical manufacturer Mipharm.
Eight Roads leads $12m Series B for India's Core Diagnostics
Eight Roads Ventures has led a $12 million Series B round for India-based medical diagnostics services provider Core Diagnostics.
China genomic services provider Novogene raises $75m
Novogene Technology, a Beijing-headquartered genomic services provider, has raised a $75 million Series B round from Chinese investors including CMB International, SDIC Innovation Investment and Shanghai Sigma Square Capital.
India's Kalaari Capital backs two domestic start-ups
Indian technology investor Kalaari Capital has invested $6 million across domestic start-ups, AffordPlan and Active Intelligence.
China's Innovent Biologics gets $260m Series D round
A fund controlled by China’s State Development & Investment Corporation (SDIC) has led a $260 million Series D round of funding for Innovent Biologics, a domestic biopharmaceutical company working on treatments for cancer, autoimmune disorders and heart...
Australia's Impact Investment raises $10m VC fund
Australia’s Impact Investment Group has raised A$13 million ($10 million) for a domestically focused venture capital fund. The initial target was A$10 million.
China’s ORI Healthcare Fund leads $100m round for UK biotech firm
ORI Healthcare Fund, a Chinese sector-focused fund launched by former investment banker at Goldman Sachs, has led a $100 million Series C round for Kymab Group, a UK bio-pharmaceutical company focused on antibody drug discovery.
Deal focus: Mitsui makes medical inroads
Having lost out to KKR when bidding for Panasonic Healthcare two years ago, Mitsui & Co. seized upon a second chance to get involved and offer the company access to its global network of medical assets